Celdara Medical, LLC today announced that the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) has awarded a two-year Small Business Innovation Research (SBIR) contract to fund the development of the novel, parasite-derived, antigen-sparing protein adjuvant ASP-1 for flu vaccines. This project builds […]
Celdara Medical, LLC today announced that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded a Phase I Small Business Innovation Research (SBIR) award to fund the company’s advancement of anti-hIAPP antibodies for the diagnosis of prediabetes and Type […]
The problem is painful and obvious: while epic sums are being spent, every day more people are dying, and we are all living with fewer freedoms. We would not choose to begin the design of our weapons after declaring war. Why did we choose to start developing life-saving medicines against infectious diseases […]
Leading Scientists Join Together to Prepare for the Next Global Pandemic CAMBRIDGE, Mass. and LEBANON, N.H. and NEW YORK, Oct. 20, 2020 /PRNewswire/ — Celdara Medical announced today the launch of the Pandemic Security Initiative’s Scientific Advisory Board (SAB), a group of outstanding scientists and infectious disease experts. The SAB is an integral part of […]
Celdara Medical, LLC today announced that DRIVEN Accelerator Hub Participant Company, CoreMap, has closed a Series A investment of $10.5 M led by Qure Ventures. The round included existing investors such as Ronny Ginor, MD of Fifth Focus/HRMG Investments and Orbimed Venture Partners, and a diverse group of new strategic, corporate, and financial partners. Of the eight companies that have participated in the NIH-funded DRIVEN Accelerator […]
CAMBRIDGE, MA. and LEBANON, NH. and NEW YORK, NY. Aug. 12, 2020 /PRNewswire/ — Celdara Medical (“Celdara”) announced that the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) has awarded a Small Business Innovation Research (SBIR) grant to fund the company’s development of […]
Celdara Medical today announced the launch of its Pandemic Security Initiative, harnessing the resources needed to prepare the nation for future infectious disease pandemics.
Celdara Medical, a clinical-stage biotechnology company focused on delivering products to patients, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and The Geneva Foundation, 501(c)3 non-profit organization that advances military medical research.
Celdara Medical announces the publication of new translational research in the American Journal of Transplantation indicating that a novel polymer therapeutic candidate, APP-103TM, is able to preserve kidney function in preclinical models of kidney ischemia reperfusion injury, including transplantation.